In 2016, Gao M. et al. discovered in both in vitro and in vivo experiments that miR-145 sensitizes breast cancer to doxorubicin by suppressing the ABC transporter multidrug resistance-associated protein 1 (MRP1) and suggested the development of MRP1 inhibitors [13]. Here, ABCC1 is linked to breast carcinoma.